Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2008; 52:599-604, doi:10.1016/j.jacc.2008.05.026
© 2008 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow View Related CVN News Brief
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (10)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Maioli, M.
Right arrow Articles by Bellandi, F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Maioli, M.
Right arrow Articles by Bellandi, F.
Related Collections
Right arrowRelated Article

Sodium Bicarbonate Versus Saline for the Prevention of Contrast-Induced Nephropathy in Patients With Renal Dysfunction Undergoing Coronary Angiography or Intervention

Mauro Maioli, MD*, Anna Toso, MD, Mario Leoncini, MD, Michela Gallopin, MD, Delio Tedeschi, MD, Carlo Micheletti, RN and Francesco Bellandi, MD

Division of Cardiology, Misericordia e Dolce Hospital, Prato, Italy.


Figure 1
View larger version (19K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 1 Flow of Patients

The enrollment criteria and the trial flow. NAC = N-acetylcysteine.

 

Figure 2
View larger version (26K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 2 End Points in the Study Groups

Incidence of primary end point (left) (absolute increase of creatinine ≥0.5 mg/dl over baseline value within 5 days after the administration of the radiographic contrast medium). Incidence of secondary end point: relative increase of creatinine ≥25% over baseline value within 5 days (middle) and within 2 days (right) after contrast agent administration. NS = no significant difference.

 




 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement